Diabetes management

Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Tuesday, August 1, 2023
University of Oxford, Obesity, NASH, Diabetes, Principal investigator, Weight loss, CT1, Fibrosis, IMPACT, Non-alcoholic fatty liver disease, Fatty liver disease, ALT, NAFLD, Human, Diabetes management, Safety, Glycated hemoglobin, Hepatitis, Pharmaceutical industry, Dietary supplement

GAITHERSBURG, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b IMPACT trial evaluating the efficacy and safety of pemvidutide in subjects with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • GAITHERSBURG, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b IMPACT trial evaluating the efficacy and safety of pemvidutide in subjects with non-alcoholic steatohepatitis (NASH).
  • Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH.
  • Subjects on 1.8 mg pemvidutide also achieved a mean weight loss of 6.2%, with continuing weight loss at the end of treatment.
  • “Initiation of the IMPACT Phase 2b trial represents an important milestone in the development of pemvidutide for NASH,” said Scott Harris, M.D., Chief Medical Officer of Altimmune.

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, February 28, 2023
Type 2 diabetes, Blood pressure, Diabetes, ET, Human, Weight loss, Fibrosis, Non-alcoholic fatty liver disease, Research, Heart rate, Three Months, Investment, ALT, Patent, Medicine, Diet, Diabetes management, NAFLD, Principal investigator, Exercise, Government, NASH, Vital signs, University of Oxford, United States Patent and Trademark Office, Glycated hemoglobin, CT1, Weill Cornell Medicine, Hepatitis, Obesity, Overweight, Cryptocurrency, Dietary supplement, Medical imaging, Pharmaceutical industry, Webcast

GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • Webcast to be held today, February 28, 2023, at 8:30 am ET
    GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
  • We expect the key endpoints of this trial to be NASH resolution and fibrosis improvement, both assessed following 24 weeks of treatment.
  • Financial Results for the Three Months Ended December 31, 2022
    Altimmune had cash, cash equivalents and short-term investments totaling $184.9 million at December 31, 2022.
  • General and administrative expenses were consistent period-over-period at $3.8 million for each of the three months ended December 31, 2022 and 2021.

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Retrieved on: 
Tuesday, December 20, 2022
Fibrosis, Fatty liver disease, Serum, MACE, NASH, Glycated hemoglobin, Risk, NAFLD, ALT, AES, BMI, LFC, Patient, Cardiovascular disease, Nature, Heart rate, Exercise, CT1, Entrepreneurship, Diabetes management, Weight loss, Salmonellosis, Hypertension, Obesity, NAS, Hepatitis, Diabetes, Hyperlipidemia, Chest pain, Medical imaging, Dietary supplement, Pharmaceutical industry, Salmonella

The trial was conducted without adjunctive diet and exercise interventions and the double-blinding of the trial was maintained during the extension study.

Key Points: 
  • The trial was conducted without adjunctive diet and exercise interventions and the double-blinding of the trial was maintained during the extension study.
  • The population of the 12-week extension trial had similar baseline characteristics as the population of the parent, 12-week Phase 1b NAFLD trial.
  • At baseline, across all treatment groups, mean BMI was 36.7 kg/m2 and mean liver fat content (LFC), as measured by MRI-PDFF, was 22.2%.
  • Type 2 diabetes was present in 26.6% of subjects and 73.4% of study subjects were of Hispanic ethnicity.

RoundingWell Chooses Jitterbit to Streamline Healthcare Integrations

Retrieved on: 
Tuesday, December 6, 2022
ADT, Laika (EHR testing framework), Diabetes management, Improper integral, Calculus, API, Patient, System

ALAMEDA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Jitterbit , the API transformation company, today announced that RoundingWell, a Nashville-based health technology company, has chosen Jitterbit to assist with the systems integration processes for healthcare provider and payer organizations.

Key Points: 
  • ALAMEDA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Jitterbit , the API transformation company, today announced that RoundingWell, a Nashville-based health technology company, has chosen Jitterbit to assist with the systems integration processes for healthcare provider and payer organizations.
  • Systems integration in the healthcare industry is exceptionally complex due to differences of data coming in from multiple sources.
  • “We’re thrilled to work with RoundingWell and help level up their data integration capabilities,” said George Gallegos, CEO at Jitterbit.
  • Jitterbit’s solution helps clinicians in RoundingWell be more productive by:
    For more information on Jitterbit, please visit:

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Retrieved on: 
Wednesday, September 14, 2022
Glycated hemoglobin, Fatty liver disease, Weight loss, Diabetes management, ALT, NASH, LFC, Nature, Obesity, Non-alcoholic fatty liver disease, Diabetes, Â, AES, NAFLD, Exercise, Serum, Heart rate, GLOBE, Principal investigator, Dietary supplement

Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks.

Key Points: 
  • Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks.
  • Mean BMI at baseline was approximately 36 kg/m2 and mean liver fat content (LFC), as measured by MRI-PDFF, was approximately 22%.
  • Twenty-seven (29%) subjects had type 2 diabetes at baseline, and approximately 75% of study subjects were of Hispanic ethnicity.
  • We are pleased with the results of this trial, including the extent of liver fat and serum ALT reductions.

Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes 

Retrieved on: 
Sunday, May 22, 2022
Health, FDA, Diabetes, Research, Science, Pharmaceutical, Biotechnology, Patient, Health, Therapy, Insulin resistance, Gastrointestinal disease, T2D, Diabetes, Fasting, DDW, Insulin, Publication, Diabetes management, Pharmaceutical industry

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today new data from its Revita-1 and Revita-2 studies.

Key Points: 
  • Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today new data from its Revita-1 and Revita-2 studies.
  • Prior publications from these open-label and sham-controlled studies have shown improvements in glycemic control and weight in subjects with inadequately controlled type 2 diabetes.
  • Fractyl Healths lead product candidate, Revita, is based on the companys insights surrounding the potential role of the gut in metabolic diseases.
  • Fractyl Health is focused on pioneering a new approach to the treatment of T2D.

Highmark Health launches diabetes management program with Onduo by Verily

Retrieved on: 
Tuesday, February 22, 2022
Newton, Health, Medicare, Physician, Population, Hospital, Allegheny Health Network, Diabetes, Mark (given name), Diabetes management, Organization, Alphabet Inc., Accreditation, LLC, Software, ACA, American Association of Clinical Endocrinologists, Type 2 diabetes, Hypertension, Patient, Quality of life, Technology, MD, Research, Program, Weight loss, Health insurance, Management, Pharmaceutical industry, Medicine, Helion, Verily, Telehealth, Highmark

PITTSBURGH and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Highmark Health is launching Well360 Diabetes Management, a virtual care program powered by Onduo, a Verily company, for adults with type 2 diabetes.

Key Points: 
  • PITTSBURGH and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Highmark Health is launching Well360 Diabetes Management, a virtual care program powered by Onduo, a Verily company, for adults with type 2 diabetes.
  • As part of Highmark Health's Living Health model , the program is designed to give members simple, personalized, and proactive support to better manage the chronic condition, improve health outcomes and reduce costs.
  • The Well360 Diabetes Management program is now available to most Highmark health insurance members who have been diagnosed with type 2 diabetes and are over 18 years of age.1 Onduo will proactively reach out to those qualified members, who can then enroll in the program by visiting the Well360 Diabetes Management web page or downloading the Onduo mobile app.
  • Employers with Highmark health insurance coverage can contact their client manager for more details on the Well360 Diabetes Management program for their members.

HAGAR GWave Awarded FDA Breakthrough Device Designation

Retrieved on: 
Tuesday, November 23, 2021
Research, Technology, Medical Devices, FDA, Diabetes, Clinical Trials, General Health, Health, Consumer Electronics, Science, Patient, CTO, Nutrition, Skin, Schneider, US Foods, Technology, Diabetes, OGTT, MD, Prediabetes, Health, Blood, University, Breakthrough, University of Washington Department of Bioengineering, Metabolism, Quality of life, View, Research, Medical director, Conditional sentence, Smartphone, FDA, Division, Diabetes management, Food, Columbia Pacific University, Glucose meter, Medical imaging, Pharmaceutical industry, Medical device

The US Food and Drug Administration (FDA) granted Breakthrough Device Designation for Hagars GWave , the world's first non-invasive continuous glucose monitoring technology that uses radiofrequency (RF) waves to measure glucose levels in the blood.

Key Points: 
  • The US Food and Drug Administration (FDA) granted Breakthrough Device Designation for Hagars GWave , the world's first non-invasive continuous glucose monitoring technology that uses radiofrequency (RF) waves to measure glucose levels in the blood.
  • Todays announcement that GWave received Breakthrough Device Designation from the FDA follows the $11.7 million Series B funding round earlier this year led by a returning investor, Columbia Pacific, that saw HAGARs total funds raised increase to $17.1 million.
  • Since its inception, the Breakthrough Device Designation has opened the door to diabetes device innovation and has sped up the development and assessment of such devices that promise more effective and safe treatments or diagnoses for this life-threatening or irreversibly debilitating condition.
  • GWave First Generation is a third of the size of a smartphone and involves less RF exposure than a smartphone.

HAGAR Secures $11.7M Series B Funding to Advance Non-Invasive Blood Glucose Monitoring Technology

Retrieved on: 
Thursday, August 12, 2021
Research, Mobile, Wireless, Technology, Medical Devices, Diabetes, Other Technology, General Health, Health, Consumer Electronics, Science, Tea, VP, Division, Organizational founder, Blood, Population, Business development, CEO, Diabetes, Conditional sentence, Nutrition, Disease, Diabetes management, CGM, Metabolism, University, Death, Innovation, Columbia Pacific University, Radio, Glucose meter, Education, RF, FDA, View, University of Washington Department of Bioengineering, Technology, Smartphone, Diagnosis, Smartwatch, CTO, Food and Drug Administration, Pharmaceutical industry, Medical imaging, Medical device, Renewable energy

HAGAR, the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, today announced an $11.7 million Series B funding round led by a returning investor, Columbia Pacific.

Key Points: 
  • HAGAR, the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, today announced an $11.7 million Series B funding round led by a returning investor, Columbia Pacific.
  • This investment brings HAGARs total funding to $17.1 million, following the $4.4 million in Series A funding it received in March 2021.
  • Raising this Series B is further confirmation of the merit of our technology a technology that we believe will transform diabetes care, said General Guy Zur, CEO, and co-founder of HAGAR.
  • (Noninvasive Glucose monitoring) is the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood continuously.

ALR Technologies Advances Partnership Discussions with Two Global Animal Health Pharmaceutical Companies

Retrieved on: 
Monday, August 2, 2021
Diabetes, OTC Markets Group, Neptune Orient Lines, Diabetes management, Companies, Transport

Ltd. (ALRT or the Company) (OTCQB: ALRT), the diabetes management company, announces today the advancement in partnership talks on the GluCurve Pet CGM with two key pharmaceutical companies in animal health.

Key Points: 
  • Ltd. (ALRT or the Company) (OTCQB: ALRT), the diabetes management company, announces today the advancement in partnership talks on the GluCurve Pet CGM with two key pharmaceutical companies in animal health.
  • One interested pharmaceutical company stated they believe the GluCurve Pet CGM will revolutionize diabetes management for pets.
  • Ltd. is a wholly owned subsidiary of ALR Technologies Inc. On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore.
  • Further management discussions of risks and uncertainties can be found in the Company's quarterly filings with the Securities Exchange Commission.